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Structural Imaging in Amyotrophic Lateral Sclerosis
According to the revised El-Escorial criteria, evidence of upper and lower motor neuron development is needed for the diagnosis of ALS.
However, there is no in vivo marker available for involvement of the upper motor neurons, and involvement of the lower motor neurons often masks upper motor neuron involvement. There is a pronounced delay between the onset of symptoms and diagnosis. Neuroimaging in ALS is mostly used to exclude other pathologies to increase the probability for the diagnosis of ALS rather than to provide definite evidence. Positive evidence may only be subtle and unspecific, although there are some signs in neuroimaging data with positive predictive value.
1 Criteria based on these findings are used for clinical diagnosis.
One of the most widely used structural imaging techniques in the clinical diagnosis of ALS is MRI, which provides high-contrast images of anatomical structures. Neuroimaging Advances in Amyotrophic Lateral Sclerosis 19 With the help of functional neuroimaging, our understanding of the pathophysiology and plasticity of the human brain has increased substantially. Cortical and subcortical plasticity in the adult human brain compensates for structural and functional deficits following neurodegeneration, atrophy and trauma. 20 In ALS, functional imaging has contributed substantially to our understanding of functional changes in the motor and extramotor systems during progressive motor neuron loss. 21, 22 In the future, fMRI may have the potential to complement the diagnostic procedures and help to determine the stage of functional loss in ALS patients.
The clinical potential of a non-invasive probe of brain function with the option of repeated measures over time (owing to the lack of radiation charge), in addition to the high feasibility of MRI scanners in many hospitals and research centres, has extended the application of fMRI in clinical science and contributed to an exponential increase in scientific publications on fMRI over the last decade.
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Functional Imaging in Clinical Settings
Study designs in clinical neuroimaging require that all paradigms are easily accomplishable by physically restricted patients, e.g. with ALS.
Frequency and applied strength in motor tasks and required reaction time have to be adjusted accordingly. In an active paradigm (e.g. fMRI), a task is performed by a subject inside the MRI scanner (e.g. hand movement or viewing images). In a passive paradigm (e.g. resting state MRI) no special task is given and subjects are asked to lie still. Using that approach, baseline cortical activity is measured.
The duration of a task has to take into account that subjects must lie supine inside the scanner for half an hour on average with minimum head movement (<1.5 mm within 5 minutes). The performance of a group of patients is usually compared with the performance of a healthy control group measured by the identical acquisition protocol. 
Functional Imaging of Extramotor Paradigms in Motor Neuron Disease
The multisystemic character of ALS has been supported by findings of functional imaging studies for cognitive, socioemotional and sensory pathways. About 2-5% of ALS patients present with an ALS/dementia complex, but there is increasing evidence that patients with classic ALS without obvious clinical evidence of cognitive deficits may have subtle changes in frontal cortical function as well. 32, 33 Cognitive impairment has been reported as more pronounced in ALS patients with a bulbar onset compared with patients with spinal onset. [34] [35] [36] [37] Longitudinal investigation of ALS patients revealed that cognitive dysfunction in ALS occurred early in the disease course and that the cognitive deficits may not progress in synchrony with motor decline, but may occur distinctly more slowly. 37 Functional neuroimaging has supported the clinical findings of frontal cortical involvement not only in patients with an ALS/dementia complex but also in patients with ALS and subclinical cognitive impairment: hypoperfusion in the frontal cortex in ALS with or without cognitive deficits measured with PET 32 and fMRI 38 and association of reduced frontal executive function and reduced activity in fronto-parietal areas measured with PET. 33, 39 There is no evidence of additional recruitment in other areas to Neurodegenerative Disease Amyotrophic Lateral Sclerosis 
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Future Perspectives
The pharmaceutical industry and clinical researchers are still looking for an objective biomarker of disease progression or functional improvement to determine the efficacy of disease-modifying agents. 23 Structural and spectroscopic non-invasive imaging techniques have been discussed as promising candidates. 43, 44 In the future, functional imaging technigues such as fMRI might add to this field as potential in vivo progress markers. 45 In the future, it can be expected that more studies will combine structural and functional neuroimaging in the same patient cohort. The two techniques complement one another. 
